Eris Lifesciences Limited — Board Meeting, 05-08-2025: Outcome of Board Meeting

Eris Lifesciences has announced a board meeting where it approved the consolidated financial results for the quarter ended June 30, 2025. The company reported a total revenue from operations of ₹773.00 Cr, with a net profit of ₹125.10 Cr for the quarter. Basic EPS stood at ₹8.66. Investors should note these results are not directly comparable to previous periods due to the acquisition of Eris Bionxt Private Limited in October 2024. The paid-up share capital also increased to ₹13.62 Cr following ESOP allotments.